TY - JOUR
T1 - Survey of members of myeloma UK on biphosphonates-associated jaw osteonecrosis
AU - Barker, K.
AU - Lowe, D.
AU - Olujohungbe, A.
AU - Low, E.
AU - Rogers, S.
PY - 2007/11
Y1 - 2007/11
N2 - Bisphosphonate jaw necrosis (BON) is defined as exposed,
avascular, non-healing bone in either the mandible or maxilla
in association with current or previous i.v. or oral bisphosphonate therapy (Marx et al, 2005). The onset of BON has been linked to trauma, such as dental extractions, but it can also occur spontaneously. The American Association of Oral and Maxillofacial Surgeons (American Association of Oral and Maxillofacial Surgeons, 2006) estimated the incidence of
necrosis related to i.v. bisphosphonates to be 0Æ8–12%. The
management of BON tends to be symptomatic relief, and cure
is difficult to achieve, hence the onus is on prevention (Barker
& Rogers, 2006).
AB - Bisphosphonate jaw necrosis (BON) is defined as exposed,
avascular, non-healing bone in either the mandible or maxilla
in association with current or previous i.v. or oral bisphosphonate therapy (Marx et al, 2005). The onset of BON has been linked to trauma, such as dental extractions, but it can also occur spontaneously. The American Association of Oral and Maxillofacial Surgeons (American Association of Oral and Maxillofacial Surgeons, 2006) estimated the incidence of
necrosis related to i.v. bisphosphonates to be 0Æ8–12%. The
management of BON tends to be symptomatic relief, and cure
is difficult to achieve, hence the onus is on prevention (Barker
& Rogers, 2006).
U2 - 0.1111/j.1365-2141.2007.06850.x
DO - 0.1111/j.1365-2141.2007.06850.x
M3 - Article (journal)
SN - 0007-1048
VL - 139
SP - 626
EP - 628
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 4
ER -